Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The decongestant are also referred as nasal decongestant which is the class of pharmaceutical drugs which is used for relieve nasal congestion in the upper respiratory tract. The active ingredient in the most of the nasal decongestant is either phenylephrine or pseudoephedrine. Intranasal corticoids are also used for decongestion and antihistamines can also use for relief from runny nose, nasal itch and sneezing. Topical decongestant on topical application as dilute solutions provides effect of vasoconstriction. Regula use of decongestant for longer duration is not suggested as it may cause atrophic rhinitis and insomnia because of vasoconstrictions.
The United States nasal decongestant market is witnessing lucrative growth during forecast period of 2021 to 2027. The decongestant are used in the treatment of nasal decongestant caused by the allergies, infections like cold, influenza and sinus infections along with nasal polyps. The dynamic factors such as growing research and development on decongestant based mucoadhesive solutions is propelling growth of United States nasal decongestant market. Increasing demanding over the counter decongestant to relieve sinus like conditions and nasal allergies is also contributing to the growth of United States nasal decongestant market. Increasing cases of allergic rhinitis and infections is also refuelling growth of United States nasal decongestant market. However, compliance of inhaling nasal sprays is hampering growth of United States nasal decongestant market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the nasal decongestant market. In addition, complete analysis of changes on nasal decongestant expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics.
The United States nasal decongestant market is segmented into product type and applications.
Products such as nasal strips, tablets, sprays and capsules are comprised in the United States nasal decongestant market. In which tablets is estimated to dominate the market in 2020. The rising use of over-the-counter medicines is propelling growth of United States nasal decongestant market. The rising incidence of self-administration of drugs is also boosting growth of United States nasal decongestant market. The rising incidence of allergies is also driving growth of United States nasal decongestant market.
Applications such as asthma, cold and nasal allergies are comprised in the United States nasal decongestant market. In which cold segment is also contributing to the growth of the United States nasal decongestion market. The common cold is a type of viral infection of nose and throat (upper respiratory tract). It is usually harmless, while it might not feel the way, Various types of viruses can cause common cold. The sneezing, runny nose, cough, sore throat, headache, nasal congestion and fever are some of the symptoms of the common cold.
The major key players in nasal decongestant market are 3M, Abbott Laboratories, Adapt Pharma Inc., Aegis Therapeutics Llc, Allergan Plc, Aptargroup Inc., Astrazeneca Plc, Bayer, Becton, Dickinson And Company, Cipla, Glaxosmithkline Plc, Innovus Pharmaceuticals Inc., Johnson & Johnson Services Inc., Meda Pharmaceuticals Inc., Merck & Co., Inc., Mylan N.V, Nastech Pharmaceutical Company Inc., Nidda Healthcare, Novartis Ag, Patrick Parsons, Pfizer Inc., Procter And Gamble, Rugby Laboratories and Sandoz International Gmbh among others.
November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Strengthening position in world’s third largest generics market.
June 2019: AptarGroup, Inc. acquired two pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC. The acquisitions are part of strategy to broaden its portfolio of services which supports pharmaceutical and biotech customers to accelerate their complex product development.
April 2019: Cipla Ltd. acquired 30% Stake in South African's Brandmed For Business Expansion. The Acquisition was carried out to pair the company’s strengths with Brandmed’s innovative, patient-centric approach to healthcare which will enhance Cipla Medpro’s portfolio.
December 2018: Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business. It is intended to improve P&G’s over the counter (OTC) geographic scale brand portfolio and category footprint across 15 markets.
The report analyses the nasal decongestant market based on product type, application and country. The various product type covered in the market are nasal strips, tablets, sprays and capsules. Based on application, the market is segmented into asthma, cold and nasal allergies. The report also analysed the impact of COVID-19 on the nasal decongestant market and it analyses that the healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report
